Express Pharma

Top 20 global biopharma companies by MCAP experience favourable Q12022

Majority of the top 20 global biopharma companies reported a 2.1 per cent increase in aggregate MCAP, from $3.4 trillion on 31st December, 2021 to $3.5 trillion as of 31st March, 2022, according to GlobalData

0 235

The top 20 global biopharma companies by market capitalisation (MCAP) experienced a favourable Q1 2022, despite global economic and financial market uncertainty. The majority of the top 20 global biopharma companies reported a 2.1 per cent increase in aggregate MCAP, from $3.4 trillion on 31st December, 2021 to $3.5 trillion as of 31st March, 2022, according to GlobalData. The leading data and analytics company noted that a positive quarter-on-quarter (QoQ) MCAP growth was reported for 14 of the top players, with four companies – Bayer (28.2 per cent), Abbvie (19.6 per cent), Vertex Pharma (19 per cent) and AstraZeneca (19 per cent) – demonstrating more than 15 per cent growth in their MCAP over Q1 2022, a statement from GlobalData said.

Mariam Shwea, MPH, Analyst, Business Fundamentals, GlobalData, commented in the statement, “Bayer and Abbvie saw the biggest growth in MCAP over Q1 2022, whereas Moderna, who previously reaped success from their COVID-19 mRNA-1273 vaccine, saw the largest decrease of -32.6 per cent in MCAP over Q1 2022.”

Shwea added, “The majority of companies maintained their ranking in Q1 2022. Johnson & Johnson, Roche and Pfizer retained the top three spots. Pfizer, however, saw a 11.8 per cent decrease in MCAP with Abbvie closing in with a MCAP increase of 19.6 per cent over Q1 2022. BioNTech, saw MCAP growth in 2021, however, did not make the top 20 list for Q1 2022.”

Johnson & Johnson maintained its top position with a MCAP QoQ growth of 3.5 per cent to $466 billion. The limited success of their COVID-19 vaccine has led Johnson & Johnson to further diversify its pipeline with oncology therapies for multiple myeloma and leukemia with the FDA approval for Carvykti in Q1 2022, a cell therapy for relapsed or refractory multiple myeloma in adults. According to GlobalData’s Drugs Database Pharma Intelligence Center, Carvykti is set to become a blockbuster, with analyst consensus global forecast sales of $4.2 billion by 2028, the state